|1.||Chen, Jiangning: 3 articles (10/2012 - 04/2010)|
|2.||Zhang, Junfeng: 3 articles (10/2012 - 04/2010)|
|3.||Giammona, Gaetano: 2 articles (05/2015 - 05/2013)|
|4.||Licciardi, Mariano: 2 articles (05/2015 - 05/2013)|
|5.||Cheng, Xiaoyun: 2 articles (10/2012 - 02/2011)|
|6.||Jiang, Xiqun: 2 articles (10/2012 - 02/2011)|
|7.||Gao, Fengbo: 2 articles (02/2011 - 04/2010)|
|8.||Kim, Da Eun: 1 article (12/2015)|
|9.||Kim, Dong-Kee: 1 article (12/2015)|
|10.||Yoon, Ji Young: 1 article (12/2015)|
05/01/2015 - "The data collected support the promising rationale of the proposed macromolecular prodrug PHEA-EDA-DOXO for further potential development and application in the treatment of solid cancer diseases."
04/01/2010 - "At a high dose of 28 mg (DOX eq.)/kg, which was lethal for free DOX to mice, PHEA-DOX could inhibit 61.5% of solid S180 tumor growth and markedly prolonged the survival time of ascetic S180-bearing mice. "
04/01/2010 - "An in-vivo antitumor study revealed that PHEA-DOX was more effective than DOX against solid S180 tumor after intraperitoneal injection at the same dose of 10 or 15 mg (DOX eq.)/kg, respectively. "
10/01/2012 - "The enhanced therapeutic effects of PHEA-MTX suggest that the PHEA-MTX conjugate may have a greater potential for chemotherapy of cancers."
09/01/2015 - "Upon uptake by cancer cells and entrapment in lysosomes (pH 5.0), the NPs disassemble to yield weak emission of TPS but strong red fluorescence of PheA with restored phototoxicity for PS activation monitoring. "
|2.||Hepatocellular Carcinoma (Hepatoma)
02/01/2011 - "The Gal-PHEA-DOX conjugate showed superior cytotoxicity against the hepatocellular carcinoma cell line HepG2 as compared with the nongalactosylated PHEA-DOX conjugate. "
02/01/2011 - "These results suggest that the Gal-PHEA-DOX conjugate has great potential for use in hepatocellular carcinoma chemotherapy because of its enhanced antitumor effect with reduced systemic toxicity including hepatotoxicity."
02/01/2011 - "This study developed a galactosyl-α,β-poly[(2-hydroxyethyl)-L-aspartamide]-doxorubicin conjugate (Gal-PHEA-DOX) and investigated its therapeutic efficacy and safety in orthotopic hepatocellular carcinoma-bearing mice. "
|4.||Body Weight (Weight, Body)
09/01/1998 - "The no-observed-adverse-effect level (NOAEL) of the enzyme preparation in the subchronic toxicity study was 2000mg/kg body weight/day (equivalent to 1152 PHEA units/kg body weight/day). "
04/01/2010 - "The toxicological effects of PHEA-DOX injected intraperitoneally in normal mice were assessed by using LD50, body weight increment, electrocardiography, blood biochemical indices, and myocardium histology, giving evidence that PHEA-DOX displayed considerably reduced systemic and cardiotoxicity compared with free DOX. "
|3.||poly(2-hydroxyethyl acrylate) (PHEA)
|4.||Aromatic Amino Acids (Aromatic Amino Acid)
|5.||Protein Sorting Signals (Signal Peptide)
|6.||Gadolinium DTPA (Magnevist)
|2.||Drug Therapy (Chemotherapy)